Abbott technology might sooner help identify severe infections, lower health care costs A new research suggests a pioneering testing technology could reduce hospital stays by up to eight times and lower annual health care costs for people who have serious infections by approximately $2.2 million). The cost reductions are based on a health economic model from the Speedy Diagnosis of Infections in the CriticAlly IlL study, today at the 54th Interscience Conference on Antimicrobial Brokers and Chemotherapy in Washington provided, D.C. This information may help doctors diagnose and initiate appropriate treatments more quickly. Additionally, the Abbott technology might offer the potential for previously discontinuation of broad-spectrum antibiotics.Acthar Gel to be provided at ACR 2015To know how auto-antibodies have an effect on systemic sclerosis in Caucasian and African-American patients, a extensive research team led by Dr. Virginia Steen from Georgetown University INFIRMARY in Washington, DC, analyzed data from the Pittsburgh Scleroderma Database. This database includes demographic, medical, autoantibody, organ involvement and survival info for 203 African-American and 2945 Caucasian scleroderma individuals seen at the University of Pittsburgh Medical Center between 1972 and 2007. Findings show that African Americans acquired higher frequencies of specific scleroderma-specific autoantibodies in comparison to Caucasians: anti-U3-RNP , U1-RNP and anti-topoisomerase . Anti-topoisomerase auto-antibodies in scleroderma are connected with an increased incidence of pulmonary fibrosis and greater disease intensity, and in this study, African-American individuals with this antibody got more frequent and more severe fibrosis than the Caucasians with this antibody.